Clinician Link.AI ™️’s Post

🎥 Explore the new frontier in anti-VEGF therapies with Dr. John Kitchens (RETINA ASSOCIATES OF KENTUCKY) as he compares the newer generation, including faricimab and Bayer | Ophthalmology 8 mg aflibercept, to older medications. Discover how Bayer | Ophthalmology Eylea HD (8 mg aflibercept) is revolutionizing treatment, allowing for fewer injections and extended treatment intervals, providing significant benefits for patients. Dr. Kitchens delves into the advantages of these advancements and how they're enhancing patient care in ophthalmology. Join us to learn how these innovations are changing the game! #COPHY2024 #EyleaHD #AntiVEGF #OphthalmologyInnovation #Aflibercept8mg #PatientCareProgress #OphthalmologyResearch #PatientCare #HealthcareEducation #retina #OphthalmologyFuture #medicalinnovation #Surgicalretina  COPHy Congress Simrat Sodhi

🌐👁️ Dive into the future of patient care with Dr. Rufino Silva at European Society of Retina Specialists (EURETINA) 2024! Dr. Silva shares groundbreaking insights on leveraging OCT and mobile technology to enhance patient monitoring. From detecting subtle changes with apps at home to utilizing peripheral OCT in clinics, these innovations aim to reduce clinic visits while ensuring effective management of conditions like PCV. 📱🔍 Discover how these technologies not only ease the treatment burden but also improve the precision in monitoring disease progression. Dr. Silva highlights the efficacy of EYLEA® HD (aflibercept) Injection HCP 8mg in delivering both anatomical and functional improvements for patients. 🎥 Stay tuned as Dr. Silva elaborates on the integration of advanced biomarkers and technology in ophthalmology, paving the way for more personalized and efficient patient care. #Euretina #Ophthalmology #EyeCare #RetinaSpecialist #MedicalInnovation #VisionHealth #EyeHealth #DigitalHealth #Retina #Ophthalmology #ClinicianLinkLive  Bayer Bayer | Ophthalmology

👁️💡 Dr. Sherveen Salek shares his positive experiences with EYLEA® HD (aflibercept) Injection HCP High Dose, a game-changer in retinal treatment. Having incorporated it into their formulary in recent months, Dr. Salek has seen remarkable results, especially in patients who previously required frequent injections. His insights highlight the potential for extending treatment intervals and enhancing patient outcomes with this advanced therapy. Join the discussion on the future of eye care and how these innovations are reshaping patient management. #ASRS2024 #Ophthalmology #MedicalLeadership #VisionaryInOphthalmology #MedicalInnovation #RetinaSpecialists #EyeCareInnovation #VisionScience #MedTech #HealthcareTrends #ClinicalResearch Bayer Bayer | Ophthalmology ASRS – American Society of Retina Specialists Saghar Bagheri MD PhD

I'm excited to share my recent experience using the new Streamline Viscocanaloplasty System from New World Medical in combination with the iStent Infinite from Glaukos for glaucoma management. This innovative approach has been instrumental in decreasing intraocular pressure (IOP) and reducing the medication burden for our patients. In the procedure, the Streamline system injects viscoelastic into Schlemm's canal, enhancing aqueous outflow. The attached video vividly demonstrates this process, showing viscoelastic and blood refluxing out of an iStent ostium as the viscoelastic is introduced. This visual evidence underscores the efficacy of combining these technologies to improve patient outcomes. Embracing such advancements allows us to offer better care and improve the quality of life for those affected by glaucoma. I'm looking forward to continuing to explore and implement cutting-edge solutions in ophthalmology. #GlaucomaManagement #InterventionalGlaucoma #OphthalmologyInnovation #PatientCare #Glaukos #NewWorldMedical #eyeassociatesofsouthtexas #jtkavanaghmd #streamline #istentinfinite #synergy

🌟👁️ Discover the clinical advantages of high-dose EYLEA® HD (aflibercept) Injection HCP through the experiences of Drs. Kenneth Fan, Sherveen Salek, and David Brown. In a compelling series of interviews, these experts discuss the effectiveness of this treatment in managing severe retinal diseases, sharing their successes in transforming patient outcomes. Learn more about the potent impact of high-dose Eylea on ophthalmic care. #ASRS2024 #Ophthalmology #MedicalLeadership #VisionaryInOphthalmology #MedicalInnovation #RetinaSpecialists #EyeCareInnovation #VisionScience #MedTech #HealthcareTrends #ClinicalResearch ASRS – American Society of Retina Specialists Bayer Bayer | Ophthalmology

🌟🔬 Coming soon live, from American Academy of Ophthalmology 2024! Join Dr. Austin Pereira as he delves into groundbreaking insights from Dr. Quan Dong Nguyen’s presentation on the Neptune Phase 2 Clinical Trial. Discover how Brepocitinib, an innovative JAK/TK inhibitor, is setting new standards in the treatment of non-infectious uveitis. 📈💊 Stay tuned for more updates as we bring you the latest in ophthalmic breakthroughs directly from Chicago! #AAO2024 #ClinicalTrials #Ophthalmology #InnovationInMedicine #ClinicianLink

Doheny in the News: Last month, SriniVas R Sadda, MD, met with Ophthalmology Times to speak about his study of SB15, looking at the impact of switching patients receiving anti-VEGF therapy to an aflibercept biosimilar, which could be a lower cost and potentially equally effective therapy. Check out the article at this link: https://bit.ly/44HsHHT

🌟👨⚕️🔬 At European Society of Retina Specialists (EURETINA) 2024, Dr. John Kitchens shares his enthusiastic insights on the innovative advancements in retinal therapy with the introduction of the new 8mg EYLEA® HD (aflibercept) Injection HCP. With experience in the U.S., Dr. Kitchens is impressed by the drug’s performance in clinical settings. 🚀💡 Explore Dr. Kitchens' firsthand observations: from its potent drying effects to its enhanced durability, the drug shows promising results, particularly for treatment-naive patients. While cautious about extending the treatment interval immediately after the initial doses, Dr. Kitchens notes significant improvements at the eight-week mark. 👀✨ The real game changer? The ability to extend the treatment intervals for stable patients, significantly reducing the frequency of their visits. Discover how this advancement is revolutionizing patient care, making treatment more manageable and less intrusive. Bayer Bayer | Ophthalmology #Euretina #Ophthalmology #EyeCare #RetinaSpecialist #MedicalInnovation #VisionHealth #EyeHealth #DigitalHealth #Retina #Ophthalmology #ClinicianLinkLive 

Our Medical Advisor, Theodore Leng, MD, MS, will head to Sweden next week to present results from the FARETINA-DME Study at the ASRS Annual Meeting. The study analyzes #RWD from the American Academy of Ophthalmology IRISⓇ Registry (Intelligent Research in Sight) to identify the 12-month real-world clinical and anatomical outcomes with #faricimab in patients with diabetic macular edema. https://hubs.la/Q02G9Fcz0 #DME #rwd #rwe

"Data are transforming medicine in ways that were unimaginable just a decade ago. In ophthalmology, data-driven care is rapidly evolving from a distant goal to a foundational element of clinical decision-making." - Cathleen McCabe, MD Read more in our newest issue of CRST "Data-Driven Care" at CRSToday.com